Leerink Partners on Halozyme Therapeutics (HALO): VRTX partnership 'validation of Hypercon'

April 7, 2026 11:08 AM

Leerink Partners analyst David Risinger reiterated a Market Perform rating and $83.00 price target on Halozyme Therapeutics (NASDAQ: HALO)The analyst ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found